Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ACC007 + lamivudine + tenofovir disoproxil fumarate versus efavirenz + lamivudine + tenofovir disoproxil fumarate in treatment-naive adults with HIV-1 infection
ChiCTR1800019041Phase 3Completed
- Sponsor
- Beijing YouAn Hospital
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ainuovirine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Beijing YouAn Hospital. Primary endpoint: Percentage of patients with HIV RNA <50 copies/mL. Started Nov 2018; status: completed.
02
Drugs
ainuovirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on ChiCTR1800019041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019041.